Seladelpar: an investigational drug for the treatment of early-stage primary biliary cholangitis (PBC)
- PMID: 36194037
- DOI: 10.1080/13543784.2022.2130750
Seladelpar: an investigational drug for the treatment of early-stage primary biliary cholangitis (PBC)
Abstract
Introduction: Generic fibrates are used off-label as add-in therapy for the management of primary biliary cholangitis (PBC) but with unproven long-term liver-related survival benefits. The recently developed fibrate, seladelpar, has shown promising results in clinical trials, but these outcomes have been previously marred by safety concerns.
Areas covered: We summarize existing treatment options in PBC and evaluate current trial data for seladelpar in relation to liver biochemistry, symptomology, and safety.
Expert opinion: Seladelpar leads to marked improvement in liver biochemistry and may improve symptoms. Safety concerns around liver toxicity appear to have been addressed. With likely increasing evidence compared to existing off-label fibrates, seladelpar has the potential as an attractive future second-line agent in PBC.
Keywords: PPAR; Primary biliary cholangitis; fatigue; fibrates; peroxisome proliferator-activated receptor agonists; pruritus; seladelpar.
Similar articles
-
Evaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis.Expert Opin Pharmacother. 2024 Aug;25(11):1517-1523. doi: 10.1080/14656566.2024.2390120. Epub 2024 Aug 11. Expert Opin Pharmacother. 2024. PMID: 39107982 Review.
-
Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis.Liver Int. 2022 Jan;42(1):112-123. doi: 10.1111/liv.15039. Epub 2021 Aug 26. Liver Int. 2022. PMID: 34403559
-
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.J Hepatol. 2022 Aug;77(2):353-364. doi: 10.1016/j.jhep.2022.02.033. Epub 2022 Mar 30. J Hepatol. 2022. PMID: 35367282 Clinical Trial.
-
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.Hepatology. 2023 Aug 1;78(2):397-415. doi: 10.1097/HEP.0000000000000395. Epub 2023 Apr 6. Hepatology. 2023. PMID: 37386786 Free PMC article. Clinical Trial.
-
New Treatment Paradigms in Primary Biliary Cholangitis.Clin Gastroenterol Hepatol. 2023 Jul;21(8):2076-2087. doi: 10.1016/j.cgh.2023.02.005. Epub 2023 Feb 19. Clin Gastroenterol Hepatol. 2023. PMID: 36809835 Review.
Cited by
-
Seladelpar: First Approval.Drugs. 2024 Nov;84(11):1487-1495. doi: 10.1007/s40265-024-02114-4. Epub 2024 Nov 22. Drugs. 2024. PMID: 39572508 Review.
-
Mechanism-based target therapy in primary biliary cholangitis: opportunities before liver cirrhosis?Front Immunol. 2023 May 30;14:1184252. doi: 10.3389/fimmu.2023.1184252. eCollection 2023. Front Immunol. 2023. PMID: 37325634 Free PMC article. Review.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources